Step 1: Submission
Complete the Notification of a Substantial Amendment to a Clinical Trial form and the amendment tool (https://www.myresearchproject.org.uk/help/hlpamendments.aspx). The Notification of a Substantial Amendment form can either be completed as part of the amendment tool or found here.
A PDF version of the form and the amendment tool should be submitted along with any documents which are being amended the new part of IRAS
Where information in the EudraCT Annex I form is being amended, an updated version of the xml should also be provided. The changes may be highlighted but this is not mandatory.
Only substantial amendments
should be submitted via this route. Amendments to studies taking place in the
NHS (or HSC in Northern Ireland) which do not meet the criteria for a
substantial amendment (substantial amendment details for REC and HRA/HCRW Approval can be found here) should be submitted via email to the REC. This is because the e-submission functionality for these types of amendments is still in development.
- A covering letter should be provided which contains the following table (in addition to what would standardly be included in the covering letter). Please indicate in the right hand column which documents are being submitted with the substantial amendment and, where relevant, the updated version number and/or document date.
|1. Substantial amendment form|
|3. Investigator's Brochure (IB)|
|4. Documentation relating to compliance with good manufacturing practice (GMP) for the investigational medicinal product|
|5. Investigational medicinal product dossier (IMPD)|
|6. Auxiliary (ie non-IMP) medicinal product dossier|
|7. Content of labeling of the investigational medicinal products|
|8. Recruitment arrangements|
|9. Subject information, informed consent form and informed consent procedure|
|10. New investigator|
|11. New site|
|12. Proof that data will be processed in compliance with union law on data protection|
|13. Other: please state below|
Step 2: Validation
Validation checks will be completed on the substantial amendment by the MHRA within 3 days. This will involve checking that all of the relevant documents (as stated in the substantial amendment table copied to the covering letter) have been submitted, and are readable, and that the correct organisation (REC/MHRA) and Part (Part I / Part II) has been selected in the system. One validation check will be undertaken for the entire substantial amendment and only one validation letter will be issued by the MHRA. For substantial amendments to trials which involve sites in the NHS, the confirmation of categorisation will not be provided with the validation but will follow shortly afterwards.
Step 3: Co-ordinated assessment
The MHRA will determine whether the substantial amendment needs to be reviewed by the MHRA, the REC or both. This will be based on the information which is provided in the substantial amendment form (section A) and the information provided in the covering letter. Substantial amendments that need to be reviewed by the REC only will not incur a fee.
Where applicable, the relevant documents will be provided to the REC by the MHRA.
Step 4: Issuing an opinion
The final decision will be issued within 35 days. This will be a single e-mail with decision letter(s) attached.
Post approval reporting
Step 1: Submission
The following post approval reports should be submitted via the following routes:
- Suspected Unexpected Serious Adverse Reaction (SUSAR)
Submission route- Eudravigilance (EV Gateway or EVWEB) or eSUSAR website
- Annual safety reports
Submission route- CESP & E-mailed directly to the REC which approved the trial.
- Annual progress report
Submisison route- E-mailed directly to the REC which approved the trial
- End of trial notifications
Submission route-CESP & E-mailed directly to the REC which approved the trial
* If the trial has ended prematurely then a substantial amendment should also be submitted where it is necessary to seek ethical review of related actions such as informing participants and arranging continuing care and follow-up outside the trial.
Please complete the end of trial notification form which can be found here.
REC only reports should be submitted directly to the REC by email.
Step 2: Acknowledgement
You will receive confirmation that the notification has been received.
Summary of version changes
|Step 1 Submission||Updated link to 'CWoW part of IRAS'||3.0||30.07.2020|
|Step 1 Submission||To remove link to EMA guidance||2.9||15.6.2020|
|Step 1 Submission||To confirm non-substantial amendments should be sent to the REC email.||2.8||4.6.2020|
|Step 1 Submission||Updated to refer to the amendment tool||2.7||1.6.2020|
|Throughout||Updated to reflect the roll out of the new part of IRAS||2.6||21.4.20|
|Addition of new site||To further confirm that new NHS/HSC site amendments do not need to be submitted through EUdralink||2.5||3.2.2020|
|End of trial notification||To become part of post approval reporting||2.5||3.2.20|
|Document title||To reflect the broader scope of the document to include post approvals submissions other than amendments and end of trial notifications||2.3||7.10.19|
|Safety reports and progress reports||Section added to confirm that these reports should continue to be submitted as per normal process||2.3||7.10.19|
|Submission||Submission of substantial amendments should be via Eudralink and no longer via IRAS (until further notice)||2.1||3.5.19|
|Submission||All substantial amendments should be numbered sequentially, including the addition of a new site and PI||2.1||3.5.19|
|Submission||The submission of a new substantial amendment when an existing substantial amendment is under review should be avoided where possible||2.1||3.5.19|
|Submission||Clarify that substantial amendments to add a new site and PI should be submitted via Eudralink||2.1||3.5.19|
|Submission||Clarification that substantial amendments which are an update to the IB should only be submitted when required||2.1||3.5.19|